About G&E

De-Ying was founded in August 2002 and was approved by the Southern Taiwan Science Park of the Ministry of Science and Technology in October 2002 as a high-tech enterprise. Drug development is an interdisciplinary mission; therefore, De-Ying’s R&D team consists of experts in biochemistry, physiology, molecular biology, pharmacology, horticulture, animal testing, and quality control analysis. The team is led by Professor Kuo Kuo-Hua, who previously served in the Department of Biochemistry at Kaohsiung Medical University for 23 years and has accumulated more than 40 years of experience in drug development. De-Ying is a botanical new drug development company with a paid-in capital of NT$589,996,000, focusing on developing natural plants into Western-medicine-grade botanical drugs to treat diseases that are currently difficult to manage clinically, including cancer, liver, gallbladder, kidney diseases, and other conditions.

De-Ying has an excellent R&D team, and its “Plant Bioactivity and Mechanism Research Center” has been approved by the National Science Council. The research talent and equipment are comparable to those of academic research institutes, making it one of Taiwan’s few professional botanical new drug development centers. The company has completed multiple government-funded new drug development projects and industry–academia collaborations. Its new drug SR-T100 gel has been approved by the Ministry of Health and Welfare for human clinical trials, completed Phase III clinical trials, and is conducting FDA-approved Phase II clinical trials in the U.S. for actinic keratosis and genital warts. The company is also developing an injectable formulation for treating malignant ascites in terminal cancer patients.

In addition, De-Ying has established government-certified extraction facilities, food production plants, cosmetic factories, and PIC/S GMP pharmaceutical plants. From contracted cultivation, quality analysis, to large-scale production, all processes can be completed within the company. Products include natural plant-based health supplements, botanical functional cosmetics, pharmaceutical products, and clinical trial medications.

On March 21, 2011, De-Ying was approved for listing on the Taipei Exchange (stock code 4911). For more than 20 years under Professor Kuo’s leadership, the company has operated with integrity, has no investments in other businesses, and holds no bank loans. All lands and facilities are fully owned by the company. De-Ying is committed to advancing the SR-T100 clinical trials while applying its technical expertise to improve drug bioavailability and therapeutic effectiveness. Its Silymarin product achieves the world’s highest pharmacopoeial dissolution rate and is used for treating previously difficult-to-treat liver, gallbladder, and kidney diseases. With continued efforts from the team, these outstanding achievements will lead De-Ying into the international pharmaceutical market and bring pride to Taiwan.

Upholding a scientific research spirit and a practical, results-oriented attitude, De-Ying ensures that its plant-based products are innovative, high-technology, effective, and trustworthy for consumers. With its leading botanical new drug development capabilities, the company is confident in establishing a reputable brand in the global biotech industry. Based on various assessments and external evaluations, De-Ying has grown into an important benchmark company in Taiwan’s botanical biotech new drug industry, contributing positively to Taiwan’s economic development and representing one of the few companies capable of fully integrated R&D to mass production in botanical new drug development.